The study found immune cells that help fight invasive breast cancer!

<

Release date: 2017-08-25


Breast cancer remains the leading cause of cancer-related deaths among women in the United States. Early detection and targeted therapy improve overall patient outcomes, but these factors also profoundly affect prognosis. The so-called "three-negative" breast cancer, which lacks estrogen, progesterone and human epidermal growth factor 2 (HER2) hormone receptor expression, cannot be targeted by existing hormonal therapies, and patient survival is poor. The claudin-low subtype of triple-negative breast cancer is characterized by a poorly specific prognosis and a significantly higher rate of immune cell infiltration in the tumor microenvironment. Although observations indicate that immune infiltration in breast cancer subtypes is inversely associated with patient outcome, the link has not been established.

Researchers at the Jon Serody Laboratory at the Lineberger Cancer Center at UNC Chapel Hill attempted to determine how tumor-infiltrating immune cells contribute to breast tumor growth and response to immunotargeting therapy. Their recent work published in JCI reported that low-density breast tumors contain large amounts of regulatory T cells (Tregs), an immune cell that suppresses the activity of the immune system. In a mouse model of breast cancer, checkpoint inhibition therapy (immunotargeted therapy) does not reduce the growth of tight junction protein tumors. Studies have determined that during checkpoint inhibition therapy, an increase in Treg interferes with immune targeting, thereby providing protection for tightly linked tumors. Consistent with this mechanism, checkpoint inhibition treatment delays tumor growth in these mice when Tregs are depleted.

These findings suggest that interfering with Treg recruitment to tumors is a potential strategy to improve targeted therapy for triple-negative breast cancer. In addition, they support the notion that determining the immune profile of a breast cancer subtype can more effectively and quickly apply an effective treatment, which may improve the patient's prognosis.

Source: Noble

enhanced bone mineral density

10% Inulin is one of the Extracts Of Chicory, which is the Key Product of our company. It is a white powder which is extracted, concentrated and dried from the stem and leaves of chicory.
Chicory, Chinese medicine name.It is a uyghur traditional medicine.Cichori-μm glandulosum boiss. et Huet or Cichorium intybus L.A dry terrestrial part or root.In summer and autumn, the upper part of the ground is cut or the roots are dug at the end of autumn to remove silt and impurities and dry in the sun.
The fleshy roots of chicory contain inulin, chlorogenic acid and bitter substances.The aboveground part contains chicory acid, crude protein, fat, fiber, etc.Chicory has antibacterial and astringent effects and can be used in the treatment of acute gastroenteritis.Chicory stimulates the central nervous system and increases heart activity.The active ingredients in chicory can regulate gastrointestinal function, anti-tumor, reduce blood lipid and cholesterol.
Chicory is antipyretic and detoxifying, diuresis and detumescence. It is mainly treated with dampness-heat jaundice, nephritis edema, epigastric distension and loss of appetite.Chicory can synthesize minerals, diuretic, stomach, tonic, increase appetite, clean stomach and digestive effect.

enhanced bone mineral density,Inulin Herb Extract,Inulin Plant Health Extract,Inulin Extract,Inulin Herb And Health Extract

Shaanxi Kepler Biotech Co.,Ltd , https://www.keplerherb.com